PMID- 31727181
OWN - NLM
STAT- MEDLINE
DCOM- 20200625
LR  - 20200625
IS  - 2072-1315 (Electronic)
IS  - 1606-0997 (Print)
IS  - 1606-0997 (Linking)
VI  - 38
IP  - 1
DP  - 2019 Nov 14
TI  - Comparison of serum amylase level between dipeptidyl peptidase-4 inhibitor and 
      GLP-1 analog administration in patients with type 2 diabetes mellitus.
PG  - 33
LID - 10.1186/s41043-019-0197-x [doi]
LID - 33
AB  - We monitored serum amylase level in patients with type 2 diabetes mellitus (T2DM) 
      prescribed either dipeptidyl peptidase-4 inhibitor or GLP-1 analog (GLP-1 group) 
      as monotherapy. Patients were treated for a 36-month period. All subjects were 
      non-smoker and did not take any alcoholic beverages. Forty-nine patients were 
      prescribed DPP4is (DPP4i group), and 9 patients were prescribed GLP-1 analogs 
      (GLP-1 group). The median of serum amylase levels in DPP4is group was 73 U/mL and 
      the median of serum amylase levels in GLP-1 analog group was 76. Thus, there was 
      no statistical significance between the two groups. However, the increased serum 
      amylase levels in the three patients were observed only in the DPP4is group. One 
      strength of the current study is that the serum amylase level was consistently 
      measured in all subjects, and those subjects had been treated with either DPP4is 
      or GLP-1 analogs as monotherapy. The incidence of elevated serum pancreatic 
      amylase levels beyond normal range was calculated as 6.12% in the DPP4is group 
      although the frequency was 0% in the GLP-1 analog group. Measurement of serum 
      amylase consistently might have clinical meaning to catch the onset of 
      pancreatitis and minimize the side effects due to DPP4is and GLP-1 analogs.
FAU - Okada, Junichi
AU  - Okada J
AD  - Department of Medicine and Molecular Science, Gunma University Graduate School of 
      Medicine, 3-39-15 Showa-machi, Maebashi, Gunma, 371-8511, Japan. 
      okadash@gunma-u.ac.jp.
AD  - Kan-etsu Chuo Hospital, 71 Kitahara, Takasaki, Gunma, 370-3513, Japan. 
      okadash@gunma-u.ac.jp.
FAU - Yamada, Eijiro
AU  - Yamada E
AD  - Department of Medicine and Molecular Science, Gunma University Graduate School of 
      Medicine, 3-39-15 Showa-machi, Maebashi, Gunma, 371-8511, Japan.
FAU - Niijima, Yawara
AU  - Niijima Y
AD  - Kan-etsu Chuo Hospital, 71 Kitahara, Takasaki, Gunma, 370-3513, Japan.
FAU - Okada, Shuichi
AU  - Okada S
AUID- ORCID: 0000-0003-1403-6840
AD  - Department of Medicine and Molecular Science, Gunma University Graduate School of 
      Medicine, 3-39-15 Showa-machi, Maebashi, Gunma, 371-8511, Japan.
AD  - Kan-etsu Chuo Hospital, 71 Kitahara, Takasaki, Gunma, 370-3513, Japan.
FAU - Yamada, Masanobu
AU  - Yamada M
AD  - Department of Medicine and Molecular Science, Gunma University Graduate School of 
      Medicine, 3-39-15 Showa-machi, Maebashi, Gunma, 371-8511, Japan.
LA  - eng
PT  - Comparative Study
PT  - Letter
DEP - 20191114
PL  - Bangladesh
TA  - J Health Popul Nutr
JT  - Journal of health, population, and nutrition
JID - 100959228
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Hypoglycemic Agents)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
RN  - EC 3.2.1.- (Amylases)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Amylases/*blood/drug effects
MH  - Diabetes Mellitus, Type 2/*blood/drug therapy
MH  - Dipeptidyl-Peptidase IV Inhibitors/*administration & dosage
MH  - Female
MH  - Glucagon-Like Peptide 1/*analogs & derivatives
MH  - Humans
MH  - Hypoglycemic Agents/*administration & dosage
MH  - Male
MH  - Middle Aged
PMC - PMC6854662
COIS- The authors declare that they have no competing interests.
EDAT- 2019/11/16 06:00
MHDA- 2020/06/26 06:00
PMCR- 2019/11/14
CRDT- 2019/11/16 06:00
PHST- 2019/02/21 00:00 [received]
PHST- 2019/10/28 00:00 [accepted]
PHST- 2019/11/16 06:00 [entrez]
PHST- 2019/11/16 06:00 [pubmed]
PHST- 2020/06/26 06:00 [medline]
PHST- 2019/11/14 00:00 [pmc-release]
AID - 10.1186/s41043-019-0197-x [pii]
AID - 197 [pii]
AID - 10.1186/s41043-019-0197-x [doi]
PST - epublish
SO  - J Health Popul Nutr. 2019 Nov 14;38(1):33. doi: 10.1186/s41043-019-0197-x.